Marketing of Personalized Cancer Care on the Web: An Analysis of Internet Websites

摘要: Internet marketing may accelerate the use of care based on genomic or tumor-derived data. However, online be detrimental if it endorses products unproven benefit. We conducted an analysis websites to identify personalized cancer medicine (PCM) and claims. A Delphi Panel categorized PCM as standard nonstandard evidence clinical utility. Fifty-five websites, sponsored by commercial entities, academic institutions, physicians, research institutes, organizations, that marketed included somatic (58%) germline (20%) analysis, interpretive services (15%), physicians/institutions offering (44%). Of 32 sites 56% specific test information (range 1–152 tests). All statistical tests were two-sided, comparisons website content using McNemar’s test. More contained about benefits than limitations (85% vs 27%, P < .001). Websites specifying statistically significantly more likely market one compared with (88% 44%, = .04).